Tirzepatide (cartridge without pen) 2.5mg/5mg/10mg/15mg| 10 vials

Description

Tirzepatide is an injectable prescription medicine that is used to treat adults with type 2 diabetes. It is prescribed along with diet and exercise to improve control of blood sugar levels. Tirzepatide can be used as a single therapy or with other diabetes medicines. Tirzepatide has been approved by the FDA as a weight-loss medication in the form of the new drug Zepbound  for patients who are overweight (BMI between 27 and 30 with at least one weight-related comorbid condition, such as dyslipidemia, hypertension, obstructive sleep apnea, diabetes, or cardiovascular disease) and patients who are obese (BMI higher than 30).

Tirzepatide acts in much the same way as semaglutide, which is the generic component in Ozempic (for weekly injection) and Rybelsus (a daily oral medication), which are approved treatments for diabetes, and Wegovy, which is approved for weight-loss.

Tirzepatide supplies single molecule dual glucagon-like peptide-1 (GLP-1) receptor agonist plus glucose-dependent insulinotropic polypeptide (GIP). Semaglutide supplies only GLP-1. Tirzepatide activates the secretion of GIP and GLP-1 receptors in the gutwhen glucose or nutrients are eaten. These stimulate the secretion of insulin from the pancreas. They can also regulate food intake control centers in the brain.

These drugs also produce substantial benefits in sustainable weight reduction.

Tirzepatide is not for use in people with type 1 diabetes.

Dosage

Tirzepatide should be injected subcutaneously once each week on the same weekday at about the same time of the day. Do not use the same site for each injection, but administer in rotation weekly in the abdomen, thigh, or upper arm.

If taking insulin and Tirzepatide simultaneously, do not inject them mixed together in the same injection. You can administer injections of Tirzepatide and insulin in the same body area, but not right next to each other.